SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:2283 5733
 

Sökning: L773:2283 5733 > Improving the manag...

Improving the management of high cost anticancer drugs in a health care system

Russi, Alberto (författare)
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy
Damuzzo, Vera (författare)
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
Serena, Marta (författare)
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
visa fler...
Gorreja, Frida (författare)
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy,Nutrition Gut Brain Interactions
Palozzo, Angelo C. (författare)
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy
visa färre...
Hospital Pharmacy, Veneto Institute of Oncology IOV-IR.C.C.S., Padua, Italy School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (creator_code:org_t)
2016-10-18
2016
Engelska.
Ingår i: Global and Regional Health Technology Assessment. - Milan, Italy : Wichtig Publishing. - 2284-2403. ; 3:3, s. 155-158
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
Abstract Ämnesord
Stäng  
  • As a consequence of the rise in cancer prevalence and in the cost of anticancer drugs, global spending for cancer is increasing rapidly. The aim of this work is to identify and assess some effective cost management parameters and possible strategies to contain expenditure. Cost limitation could be achieved by implementing effective prevention measures and other main actions: diffusion of tailored therapies; systematic postmarketing reviews; cost-effectiveness assessment; accurate treatment choices; more transparent and effective managed entry agreement policies; waste management through personalized dose preparation. To better manage high cost anticancer drugs, oncologists and hospital pharmacists should collaborate in choosing the right drug, for the right patient, at the right time. In addition, besides promoting the use of biosimilars and generic drugs, when different products have a similar clinical effectiveness, a cost-minimization analysis should be performed to identify the best clinical approach at the lowest cost. With the same purpose, verifying real life outcomes by managing postmarketing analyses helps to renegotiate price agreements in a value-for-money model; this could be arranged if the regulatory agencies renegotiate the previously established price within a defined time period. Finally, the centralization of high-cost drug preparation and the implementation of a drug-day (vial sharing) will reduce drug waste.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)

Nyckelord

Drug expenditure
managed entry agreement
oncology
preparation waste
postmarketing register
Hälso- och sjukvårdsforskning
Health and Medical Care Research
Economics
Nationalekonomi

Publikations- och innehållstyp

vet (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy